NCT07194980
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 10 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Start date pushed from Oct 15, 2026 to Dec 1, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 60 words
- Secondary endpoints: details revised at 9 of 12 entries
- Site details revised
- Collaborators: details revised at 1 of 1 entry
- Notable Start date: Sep 1, 2026 to Oct 15, 2026
- Eligibility criteria expanded, about 22 words
- Site contact updated
- Notable Start date: Aug 1, 2026 to Sep 1, 2026v10
- Notable Start date: Jul 1, 2026 to Aug 1, 2026v9
- Notable Start date: May 29, 2026 to Jul 1, 2026v8
- Notable Recruitment opened
- Start date: Jul 1, 2026 to May 29, 2026
- Site details revised
- Notable Start date: Apr 1, 2026 to Jul 1, 2026v4
- Notable Start date: Dec 2025 to Apr 1, 2026v3
- Notable Start date: Oct 2025 to Dec 2025v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Patients receive nemtabrutinib PO daily on days 1-28 of each cycle (NOTE: nemtabrutinib is not given during lymphodepleting therapy). Cycles repeat every 28 days for up to 1 year after lisocabtagene maraleucel infusion in the absence of disease progression or unacceptable toxicity. Patients undergo leukapheresis 7 days after start of nemtabrutinib treatment. Patients receive SOC lymphodepleting therapy consisting of cyclophosphamide IV and fludarabine IV on approximately the 5th, 4th, and 3rd day prior to lisocabtagene maraleucel infusion. Patients then receive lisocabtagene maraleucel IV 36-96 hours after completion of SOC lymphodepleting therapy. Patients also undergo TTE or MUGA during screening, and PET/CT scans, bone marrow biopsy and aspiration, lymph node biopsy, and blood sample collection throughout the study.
Drugs: Nemtabrutinib
Biologicals: Lisocabtagene Maraleucel
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States